$PSID “OTC Tip Reporter” Promoter Rank: 14/38 PositiveID Corp. Newsletter 7:14:32 PM February 7, 2018

on February 7, 2018 Newsletters and Tags: , , , , , , , , , , with 0 comments

Overall Perfomance for "OTC Tip Reporter"

The following three charts can be used by potential investors to gauge the performance of "OTC Tip Reporter":

45%

105 out of 229 campaigns closed down on first day

44%

102 out of 229 campaigns closed up on first day

9%

22 out of 229 campaigns had no net effect

PSID Promotional Newsletter

The following is a newsletter released by "OTC Tip Reporter" promoting PositiveID Corp.

Caution

The following newsletter has not been verified for accuracy or completeness.

OTCtipReporter

Reports Wall Street's Top Emerging Growth Companies

PSID New Blockbuster Biotech Pick For Thursday

Dear Fellow Trader,

One of our most recent Hemp picks has seen some tremendous success. We started showing it to you at $.008 back in Nov and we have seen recent highs of $.048 on Friday Jan 26th representing 464% in Gains from my alert.

Where else are you seeing gains like that

It's time for you to grab hold to another potential 100%, 200% or even 500% gainer.

Im unleashing what could turn out to be my biggest alert of February and that says a lot considering that just over a week ago my most recent Hemp pick gained 464%...

I've isolated a Tiny Biotech situation with Extensive Patent Portfolio and massive upside potential.

Your Next Step Is To Get Yourself Ready
For Thursdays Blockbuster Biotech Pick PSID

I am Issuing an Immediate Alert on PSID

My New Blockbuster Biotech Pick for Thursday is PSID

Pay close attention because this is the EXACT Catalyst
that could potentially ignite this stock to new levels.

PSID has been making tremendous progress, and has been accomplishing one major milestone after another, with accomplishments like their recent huge news of the Companys successful detection of the influenza virus on its FireflyDX prototype system and its publication of a white paper

PSID could be potentially setting up to be a major player in this billion-dollar sector.

In the United States of America, for example, recent estimates put the cost of influenza epidemics to the economy at US $71-167 billion per year. According to International Journal of Economics Management Sciences.

This year's flu season is already the most widespread on record health officials say, according to an article in the Washington Post.

This years flu season could be the deadliest in years and the most expensive

This flu season is on track to be the worst in nearly a decade. With tens of thousands of patients flocking to hospitals and at least 37 children dead, this years flu season is shaping up to be the worst in nearly a decade and its not over yet.

Early detection is key to preventing the spread of
ordinary seasonal and pandemic flu.

Pandemic influenza is rated among the gravest national risks on the government risk register. Pandemics can occur with unpredictable frequency, infecting populations with a new virus over a relatively short period of time, causing significant illness and mortality and disrupting the function of normal communities. Early detection is key to preventing the spread of ordinary seasonal and pandemic flu. According to Professor Ingemar Cox.

PositiveIDs FireflyDX prototype system has successfully detected influenza virus

The FireflyDX family of products is designed to provide accurate, rapid pathogen detection at the point-of-carepoint-of-need POCPON using real-time PCR in less than 30 minutes, with minimally trained personnel and at a lower cost than existing systems.

Current solutions for accurately identifying potential pathogens and bio-threats, especially at the POCPON, can sometimes take as long as several hours to several days to provide results, dramatically delaying what is often life-saving treatment, while also increasing costs, both personal and financial.

PositiveID and its ExcitePCR subsidiary are developing FireflyDX, in both portable and handheld forms, to enable accurate, fast, safe, cost-effective diagnosis in the field, which may offer a highly disruptive breakthrough in combating influenza, which is often diagnosed with a rapid influenza detection test RIDT. RIDTs are not as accurate, however, as lab-based testing such as PCR. In fact, the CDC recommends that if an important clinical decision is affected by a flu test result, the RIDT result should be confirmed by a molecular assay such as PCR.

According to the CDC, this years flu season is geographically widespread and patients health complications are abnormally high, stated William J. Caragol, Chairman and CEO of PositiveID. Unfortunately, as is often the case, because lab-based testing demands both significant time and financial resources, many people being tested at the point of care or point of need with rapid influenza detection tests are getting results that are only partially accurate, or worse, not accurate at all. This may allow the flu epidemic to worsen. Fast, affordable point-of-need diagnostics should be the first line of defense, and we are developing our technology to offer just such a solution, continued Caragol.

In addition to influenza virus, the FireflyDX prototype system has also successfully detected a number of other pathogenic organisms including Zika, Ebola, E. coli, influenza, MRSA, MSSA, C. diff and others.

PSID has been making tremendous progress, and has been accomplishing one major milestone after another, with accomplishments like their recent huge news that PositiveID's FDA-cleared next generation Caregiver thermometer with Bluetooth capability will be commercially available in January 2018.

Another major milestone accomplishment is PositiveIDs E-N-G Mobile Systems 2017 Bookings Increase 100% Year Over Year. They recently announced that 2017 bookings for its E-N-G Mobile Systems ENG subsidiary increased over 100% from 2016, driven primarily by growth in ENGs mobile labs bookings.

We've been waiting for an undervalued Biotech play with Blockbuster potential and huge upside potential to come along.

PSID was trading as high as $0.04 cents in Sept and has a long history of explosive pops, back in July PSID rocketed up 200% in Gains fast.

We've been waiting patiently for the perfect opportunity for PSID, and it appears the time is now with it at its current level.

A move back to its Sept high of $.04 cents per share, would show traders gains of over 3,537%

PSID looks to be in a great position right now and numerous recent developments could lead to strong upside.

With so much in the pipeline for PSID, a major breakout could be IMMINENT

I strongly suggest you start your research on PSID as I am anticipating this one to run like crazy

I am urging all of our members to add PSID to the top of their watch list right now, and be ready Thursday morning at the opening bell.

Yours for greater profits,
1 Newsletter
Longest Running MicroCap Newsletter
Editor In Chief, OTCtipReporter

DON'T MISS ANOTHER HOT OPPORTUNITY TO MAKE HUGE PROFITS

Most Trusted Name in Investor Awareness Campaigns

Help Spread the word about OTCtipReporter
You can call us toll free at 1-800-850-9305
Offices are open Monday through Friday, 930 am to 400 pm EST

Investor Awareness and IR Services
If you are interested in our Investor Awareness and IR Services
Contact us at 1-800-850-9305

Want Our Alerts FASTER than the Rest
FREE Mobile Text Alerts

Text the word STOCK to 313131
The FASTEST Way to get our Alerts

Sources

1.

2.

3.

4.

5.

6.

7.

GENERAL NOTICE AND DISCLAIMER - PLEASE READ CAREFULLY
The companies that are discussed on OTC have not approved the statements made. This opinion contains forward-looking statements that involve risks and uncertainties. A company's actual results could differ materially from those described in any forward-looking statements or announcements discussed herein. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. OTC is not a licensed broker, broker dealer, market maker, inve-st-ment-ban-ker, inve-st-ment advisor, ana.lyst or underwriter. Nor are any of its officers, affili-ates, or employees. Please consult a broker before purchasing or selling any securities viewed on OTC or mentioned herein. Affiliates, officers, directors and employees of OTC may have also b.ought or may b.uy s.hares of companies mentioned herein and may profit in the event those shares rise in value. OTC will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell each inves-tor must make their own decision based on his or her judgment of the market. This advertisement is not a solicitation or recommendation to buy, sell or hold securities and does not provide an analysis of the financial position of the company. We recommend you use the information found in this advertisement as an initial starting point for conducting your own research on the advertised company in order to determine your own personal opinion of the company before inve-st-ing. All statements and opinions contained in this advertisement are the sole opinion of the authors and are subject to change without notice. We are not liable for any inve-st-ment decisions by our readers. Readers should independently inve-st-igate and fully understand all risks before inve-st-ing. It is strongly recommended that any purchase or sale decision be discussed with a financial adviser or broker prior to completing any such purchase or sale decision. We are not registered inve-st-ment advisers, or broker-dealers, or members of any financial regulatory bodies. Furthermore, our associates andor employees andor principals may have stock positions in advertised companies purchased in the open market or in private transactions. These positions may be liquidated, without prior notification, even after we have made positive comments regarding the advertised company. The receipt of this information constitutes your acceptance of these terms and conditions. Reading this advertisement shall not create under any circumstances an offer to buy or sell stock in any company advertised. Nor shall it create any principal-agent relationship between the reader and us. Void where prohibited. Information within this advertisement contains forward looking statements within the meaning of Sec.tion-27a of the U.S. Sec.ur.ities A.c.t-of-1.9.3.3 and Section 21e of the U.S. Sec.ur.ities Exch.ange A.c.t-of -1.9.3.4. Neither OTC, its officers, affiliates, or employees is a brok.er-de.aler. The information on OTC, including the opin.ions expressed and the statements made within, is for informational and advertising purposes only and should not be construed as inve-st-ment-advice, and does not constitute an offer to sell any sec.ur.ities, nor is it to be construed as a solicitation to purc.hase any securities in any state or other jurisdiction where the offer or sale is not permitted. The information to prepare this report is believed to be from reliable sources, but no representation is made as to the accuracy or completeness of such information. Inve-st-ment in securities carries a high degree of risk and involves risks and uncertainties, which may result in inve-st-ors losing all of their inve-st-ed capital. Past performance does not guarantee future results. The information contained herein contains forward-looking statements, within the meaning of Sec.tion-27.A of the Sec.ur.ities A.c.t-of-1.9.3.3 and Sec.tion 21.E of the Sec.ur.ities Exch.ange A.c.t-of-1.9.3.4. Forward-looking statements are based upon expectations, estimates and projections at the time the statements are made and involve ris.ks and uncertainties that could cause actual events to differ materially from those anticipated. Forward-looking statements may be identified through the use of words such as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should, or might occur. Any statements that express or involve predictions, expectations, beliefs, plans, projections, objectives, goals or future events or perfor-mance may be forward-looking statements. Factors that could cause actual results to differ materially include but are not limited to adverse economic conditions, intense competition, lack of meaningful research results, inadequate capital, termination of contracts or agreements, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other key personnel, and other risks detailed in the reports filed with the Sec.ur.ities and Exch.ange Comm.ission by the companies who are mentioned in this periodical. Readers should consult with their own professional inve-st-ment, tax and portfolio advisors before making any inve-st-ment decision and should independently verify all information herein. More complete information about any of the companies mentioned in this periodical is available from the website of the Sec.ur.ities and Exch.ange Comm.ission, at sec, and copies of their filings may be read without charge and copies obtained at prescribed rates from the public reference facilities of the Comm.ission, at 450 Fifth Street, NW, Washington, DC 20549.

Buying and Selling of Shares
OTC intends to sell its shares. OTC may sell its shares for less than tar.get pri.ces given in opin.ions. OTC affiliates, officers, directors and employees may have also bought or may buy the shares discussed in this report and may profit in the event those shares rise in value. OTC will not adv.ise as to when it decides to sell and does not and will not offer any opin.ion as to when others should sell each inve-st-or must make that decision based on his or her judgment of the market. There are risks involved Always remember that OTC are not ana.lysts and inve-st-ing in sec.ur.ities such as the ones listed within are for high ri.sk tolerant individuals only and not the general public. Whether you are an experienced inve-st-or or not you should always consult with a broker before purch.asing or selling any sec.uri.ties viewed on OTC. If at any time you wish to be removed from our list simply unsubscribe in any of the previous emails sent to you.

17B DISCLAIMER
OTC is owned and operated by LionsGate Ventures Inc.. LionsGate Ventures Inc. and its owners, and their affiliates, directors and officers, and immediate family members, are hereafter collectively referred to as OTC or we or us or our. OTC electronically disseminates information the Information on its website, in newsletters, featured reports, spam compliant double-opt in email communications or otherwise pertaining to Profiled Companies' the Issuer or Issuers or Profiled Company or Profiled Companies, the sec.ur.ities of which are most frequently common stock shares quoted on the Over the Counter Bulletin Board OTCBB or Pin.k Sh.eets. The Information is based on information received from Issuers, publicly available information, such as quarterly with unaudited financial statements and annual reports with audited financial statements filed with the Sec.ur.ities and Exch.ange Comm.ission S.E.C, quarterly and annual unaudited fin.ancial reports and Information and Disclosure Statements filed with the Pink Sheets, the Issuer's website and information obtained through search engines such as Yahoo Finance, Market Watch and Business Wire. We synthesize the Information from these informational sources for our Readers as a starting point for further inquiry into the Issuer and its securities. Because OTC receives compen.sation for OTC's dissemination of the Information as disclosed in our Compe.nsation Disclosure Secti.on, including at times in the form of common stock shares the Shares, OTC should not be considered to be an independent provider of the Information. OTC is not a rese.arch ana.lyst, reg.istered inve-st-ment adv.isor or reg.istered sec.ur.ities bro.ker dea.ler and the Information should not be construed in any manner, shape or form as inve-st-ment-advice, inve-st-ment recomm.en.dations or opin.ions or viewpoints regarding the Profiled Company or its sec.ur.ities or as a solic.ita.tion to offer, purc.hase or sell the Profiled Company's sec.ur.ities. OTC does not endorse, independently verify or assert the truthfulness, completeness, accuracy or reliability of the Information and conducts no due diligence whatsoever of the Profiled Companies. Because the Information is presented on an as is basis, your use of the Information is at your own risk. OTC disclaims, expressly and impliedly, all warranties of any kind, including whether the Information is accurate or reliable or free of errors. By reading the Information, the Reader hereby agrees to indemnify and hold OTC harmless from any liability for any claimed direct, indirect, incidental, punitive, or consequential damages pertaining to the Information. Statements contained in the Information that are not historical facts are forward looking statements that involve risks and uncertainties as indicated by words such as believes, expects, estimates, may, will or should or anticipates or similar expressions. These forward looking statements may materially differ from the Issuer's actual operational and financial results or its actual achievements, claimed or otherwise. OTC does not undertake any responsibility whatsoever of these forward looking statements, nor any legal obligation whatsoever of updating the Information. The Information is presented only as a brief snapshot of the Profiled Company and should only be used, at most, and if at all, as a starting point for Readers to conduct a thorough inve-st-ig-ation of the Profiled Company and its sec.ur.ties, to consult with their financial, legal or other advisors and avail themselves of filings and information that may be accessed at sec or pin.k shee.ts or other electronic medium, including a reviewing S.E.C periodic reports For.ms 10-.Q and 10-.K, reports of material events For.m 8.-K, insi.der rep.orts For.ms .3, .4, .5 and Sch.edule 13.D b reviewing Inform.ation and Disc.losure Statem.ents and unaudited finan.cial reports filed with the Pin.k She.ets c obtaining and reviewing publicly available information contained in commonly known search engines such as Google and e consulting inve-st-ment guides at s.e.c and fin.ra pertaining to the risks of inve-st-ing in pe.nny s.tocks. In the end result, Readers must evaluate and bear all the risks associated with the Information, including reliance on its accuracy, completeness or usefulness. In all instances, the Reader should conduct further inquiry into the Profiled Company and its sec.ur.ities. The Profiled Companies are subject to possible r.isks, including but not limited to a the Information pertains to pen.ny sto.cks that are subject to the S.E.C's penny stock rules and commonly involve a high degree of risk that may result in the loss of some or all of an investment in the Profiled Company's securities b the Issuer's p.enny st.ock may be thinly traded, which may lead to difficulties of sellin.g its sec.ur.ities c the S.E.C reporting issuer may be delinquent not current in its periodic reporting obligations i.e., in its quarterly and annual reports or the P.ink Sh.eet quoted company may be delinquent in its P.ink Shee.t reporting obligations as indicated by Pin.k Shee.ts New Service's posting a negative sign pertaining to the Issuer at pi.nk she.ets, as follows i Lim.ited Inform.ation for companies with fina.ncial reporting problems, economic distress, or that are unwilling to file required reports with the P.ink Sh.eets ii P.ink Sh.eets - No Information, which indicates companies that are unable or unwilling to provide disclosure to the public markets, to the S.E.C or the Pin.k Sh.eets and iii Cave.at Emp.tor, signifying B.uyer B.eware that there is a public interest concern associated with a company's ill.egal sp.am campaign, questionable stoc.k pro.mo.tion, known inves.tig.ation of a company's fraud.ule.nt activ.ity or its insi.ders, regul.atory sus.pen.sions or disr.uptive corporate acti.ons d whether the Issuer is a development stage company with little or no operations, the securities of which should be considered extremely speculative for inve.stm.ent purposes e OTC's selling of an Issuer's sec.ur.ities may cause its stock pric.e to significantly dec.line, especially when such sec.ur.ities are thinly trad.ed f many companies that have their securities quoted on the OTCBB or Pink Sheets as well as even Exch.ange liste.d companies have been neg.atively affected by the current economic down.turn and lack of adequate fina.ncing to meet their operational goals or expansion plans g any percentage gain from the previous day close presented on our website at is not and should not be construed as any indication whatsoever of the future st.ock p.rice of an Issuer's sec.uri.ties or its operational results h many of the energy related and other Profiled Companies are subject to increasing environmental and other governmental regulations, which subjects them to significant costs and possible fines and liabilities for failure to comply with applicable state and federal statutes i OTC may receive compensation in shares of the Issuer and it or its associates, affiliated entities, officers, directors or immediate family members may se.ll the S.hares immediately upon their receipt as well as during the dissemination of such Information or within hours, days, weeks or months thereafter, or at any time as a result, OTC's selling activities may cause significant volatility in the Issuer's stock price andor significantly depress the Issuer's stock price j OTC may buy and sell the Shares in the open market before, during or after the dissemination of the Information or at any time, which may cause significant volatility including dro.ps in the pric.e of the Issuer's stock pri.ce andor significantly depress the Issuer's stock price k future success of many OTCBB and Pink Sheet quoted Issuers is dependent upon receiving adequate fina.ncing or rais.ing sufficient capital, which they may be unable to obtain l there is an inherent and actual conflict of interest that exists between our Readers' interests and OTC's interests because OTC's owners, OTC i receive the Sha.res as comp.ensation for disseminating the Information and thereafter sell those Shares at any time for monetary gain, including at the same time the Information is being disseminated or shortly thereafter or at any time and ii buys and sells the Profiled Company's shares in the open market at the same time or before the Information is being disseminated or shortly after the dissemination of the Information or at any time m we do not receive any direct verification from the Issuer regarding the Information n a third party shareholder may have a potential or actual conflict of interest in paying OTC for the dissemination of the publication while still holding the Issuer's shares of common stock that he or she may sell after the third party shareholder has paid OTC with his or her shares o the Information should not be interpreted in any shape, form or manner whatsoever as an indication of the Issuer's future stock price or future financial performance since, among other reasons, such comparison companies are listed on exchanges i.e., the New York Stoc.k Exch.ange and trade at sto.ck pri.ces that are thousands of percent higher than the companies we profile and p Readers may encounter difficulties determining what information contained in our publications is material or non-material making it all the more imperative that they conduct further inve-st-iga-tion of the Profiled Company and its sec.ur.ities and q OTC hires third party Service Providers to electronically disseminate live news regarding the Issuer, information which we do not independently provide to the Service Provider or verify and upon which we have no control over. We pay cash consideration to the Service Providers no securities compensation is paid to the Service Providers and r our employees post messages on their individual message boards as a method of disseminating the Information on behalf of our Issuer clients which should never be used as a means of conducting analysis into the Issuer and should only be used as a starting point to obtain the names of pink sheet or OTC Bulletin Board. This message is meant for informational and educational purposes only and does not provide invest.ment advice. Never make invest.ment decisions based on anything we say. To date we have been compensated Sixty Thousand dollars USD to profile PSID. Please be advised we have been additionally compensated for investor relations and media services for PSID in the amount of Twenty Five Thousand dollars USD by, a non-affiliated third party Silicon Valley Marketing LLC for marketing exposure. We do not own any shares of PSID.
.
CAUTION IT IS POSSIBLE THAT ALL MONIES MAY BE LOST OR IMPAIRED DUE TO THE SPECULATIVE NATURE OF THE COMPANIES PROFILED.

HOT OTC Picks

Breaking News Alerts

Promoted Penny Stocks

OTC NEWSLETTER

OTC Tip Reporter Reports Wall Street's Top Emerging Growth Companies in our free penny stock Newsletter daily.

OTC Tip Reporter continues to put out the best penny stock picks in today's penny stock market.

Our exceptional accuracy for big penny stock winners is apparent by our large membership.

OTC Tip Reporter is one of the longest running and most consistent newsletter in the penny stock market.

OTC Tip Reporter is ranked as one of the top performing micro-cap investment newsletters in America.

Most Trusted Name in Investor Awareness Campaigns

OTC TIP REPORTER ALERTS

OTC Tip Reporter
Get Hot Picks

JOIN US ON TODAY

Copyright 2000-2017 OTC Tip Reporter.